Effect of remdesivir on mortality rate, need of intubation and mechanical ventilation in COVID-19 positive patients: a retrospective observational study

Authors

  • Anand Nikalje Department of Medicine, MGM Medical College and Hospital, Aurangabad, Maharashtra, India
  • Srabani Tripathy Department of Medicine, MGM Medical College and Hospital, Aurangabad, Maharashtra, India
  • Rahul S. Talekar Department of Medicine, MGM Medical College and Hospital, Aurangabad, Maharashtra, India
  • Sumedh B. Mane Department of Medicine, MGM Medical College and Hospital, Aurangabad, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20231635

Keywords:

Mechanical ventilation, Remdesivir, SARS-CoV-2

Abstract

Background: The symptoms of SARS-CoV-2 infection vary widely, from asymptomatic disease to pneumonia and life-threatening complications, including acute respiratory distress syndrome, multisystem organ failure, and ultimately, death. Remdesivir has broad spectrum of activity against members of several virus families, including filoviruses and coronaviruses. Remdesivir is a potent inhibitor of SARS-CoV-2 replication in human nasal and bronchial cells.

Methods: This is a prospective and observational study conducted in patients of either gender, age more than 18 years with confirmed diagnosis of COVID-19 by RT-PCR. A predesigned, pretested and semi structured questionnaire containing socio demographic details like age, sex, BMI, comorbidities, findings of systemic examination of the cases, dose and duration of Remdesivir received and adverse effect due to therapy was used to collect the data.

Results: Mean age of the patients were 56.19±10.93 years. Male patients were 66% and 34% patients were female. After receiving the remdesivir, 43% of the patients needed bag mask and 27% of the patients maintained on room air oxygen. Non-invasive ventilation required in 19% of the patients and 11% of the patient required mechanical ventilation. s14% of the patients needed admission in the ICU. 3.5% of the patients were died and 96.5% patients were discharged from the hospital.

Conclusions: Remdesivir reduces the need of non-invasive oxygenation and mechanical ventilation. Mortality was seen in 3.5% patients, henceforth remdesivir, is an effective drug for moderate to severe COVID-19, if given in early stages of infection.

References

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157-60.

Total cases of corona in world, 2022. Available at: https://www.google.com/search?client=firefox-b-d&q=total+cases+of+corona+in+world. Accessed 31 December 2022.

Fauci AS, Lane HC, Redfield RR. Covid-19 navigating the uncharted. N Engl J Med. 2020;382(13):1268-9.

Mahase E, Kmietowicz Z. Covid-19: doctors are told not to perform CPR on patients in cardiac arrest. BMJ. 2020;368:m1282.

Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395(10229):1014-5.

Mishra AK, Sahu KK, George AA, Lal A. A review of cardiac manifestations and predictors of outcome in patients with COVID-19. Heart Lung. 2020;49(6):848-52.

Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020;13(5):667-73.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020;323(13):1239-42.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-582 infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.

Dai W-c, Zhang H-w, Yu J, Xu H-j, Chen H, Luo S-p, et al. CT Imaging and Differential Diagnosis of COVID-19. Cana Associa Radiol J. 2020;71(2):195-200.

Ryu S, Chun BC, Korean Society of Epidemiology -nCo VTFT. An interim review of the epidemiological characteristics of 2019 novel coronavirus. Epidemiol Health. 2020;42:e2020006.

De Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020;117(12):6771-6.

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):3653.

Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Comm. 2020;11(1):222.

Mulangu S, Dodd LE, Davey Jr RT, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293-303.

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-5.

Brown AJ, Won JJ, Graham RL, Dinnon III KH, Sims AC, Feng JY, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic delta coronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate Use of Remdesivir for Patients with Severe COVID-19. N Engl J Med. 2020;382:2327-36.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813-36.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.

Spinner CD, Gottlieb RL, Criner GJ, López JR, Cattelan AM, Viladomiu AS, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. Jama. 2020;324(11):1048-57.

Abd-Elsalam S, Salama M, Soliman S, Naguib AM, Ibrahim IS, Torky M, et al. Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial. Am J Trop Med Hyg. 2021;106(3):886-90.

Dai H, Saccardo S, Han MA, Roh L, Raja N, Vangala S, et al. Behavioural nudges increase COVID-19 vaccinations. Nature. 2021;597(7876):404-9.

Wajekar SD, Kurundkar GB, Shah PP, Kadam DB, Bhat SM. A comparative study of the course and outcome in hypoxic COVID-19 patients with and without comorbidities. Med J DY Patil Vidyapeeth 2022;15(Suppl S1):49-54.

Herzog Tzarfati K, Gutwein O, Apel A, Rahimi‐Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies. Ame J Hematol. 2021;96(10):1195-203.

Głowacka M, Lipka S, Młynarska E, Franczyk B, Rysz J. Acute Kidney Injury in COVID-19. Inter J Mole Sci. 2021;22(15):8081.

Ismail TS, Bhangale CS, Mahajan HM, Gaikwad VB. Drug prescribing pattern and clinical outcome in intensive care unit of a Dedicated COVID Hospital: A retrospective observational study. Natl J Physiol Pharm Pharmacol. 2022;12(04):472-6.

Balasubramanian A, Khandelwal PN, Zaveri HT, Gandhi M, Ray I, Bhusare D. Drug utilization study in patients affected with COVID-19 in a dedicated COVID hospital. Natl J Physiol Pharm Pharmacol. 2023;13(01).

Sharma A, Jain M, Yadav R, Rathi P. Managing comorbidities in Covid-19 patients: A drug utilization study in a COVID-dedicated hospital in Northern India. J Family Med Prim Care 2021;10(9):3387-94.

Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209-21.

Olender SA, Perez KK, Go AS. Remdesivir for severe COVID-19 versus a cohort receiving standard of care [published online ahead of print, 2020 Jul 24]. Clin Infect Dis. 2020:ciaa1041.

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020;383(19):1827-37.

WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. New Eng J Med. 2021;384(6):497-511.

Downloads

Published

2023-05-29

How to Cite

Nikalje, A., Tripathy, S., Talekar, R. S., & Mane , S. B. (2023). Effect of remdesivir on mortality rate, need of intubation and mechanical ventilation in COVID-19 positive patients: a retrospective observational study. International Journal of Research in Medical Sciences, 11(6), 2156–2161. https://doi.org/10.18203/2320-6012.ijrms20231635

Issue

Section

Original Research Articles